Leung Yvette, Panaccione Remo
Division of Gastroenterology, Department of Medicine, University of Calgary, 3280 Hospital Drive Northwest, Calgary, Alberta T2N 4N1, Canada.
Division of Gastroenterology, Department of Medicine, University of Calgary, 3280 Hospital Drive Northwest, Calgary, Alberta T2N 4N1, Canada.
Gastroenterol Clin North Am. 2014 Sep;43(3):619-30. doi: 10.1016/j.gtc.2014.05.013.
Despite the success of antitumor necrosis factor (TNF) therapy in Crohn's disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully human monoclonal immunoglobulin antibody that targets the interleukin (IL)-12 and IL-23 shared P40 subunit. It has been studied in 2 phase 2 randomized, double-blind, placebo-controlled trials in Crohn's disease. This article reviews the clinical efficacy and safety data of ustekinumab in Crohn's disease in anticipation of the final results of the phase III development program in moderate to severe Crohn's disease.
尽管抗肿瘤坏死因子（TNF）疗法在克罗恩病治疗中取得了成功，但仍需要针对该疾病其他免疫途径的生物疗法。乌司奴单抗是一种全人源单克隆免疫球蛋白抗体，靶向白细胞介素（IL）-12和IL-23共有的P40亚基。它已在两项克罗恩病的2期随机、双盲、安慰剂对照试验中进行了研究。本文回顾了乌司奴单抗在克罗恩病中的临床疗效和安全性数据，以期获得中重度克罗恩病III期开发项目的最终结果。
